EU Generic Approvals Could Accelerate By Two Years With Bolar Changes
The European Commission's proposed patent reforms could accelerate the approval of generic drugs by two years.
You may also be interested in...
FDA is developing a rule to describe criteria for a range of ways to offer drug treatment options to patients not participating in clinical trials.
Amarin expects to file an NDA for the morphine-releasing rectal suppository Moraxen by second-half 2002.
The European Committee on Proprietary Medicinal Products is considering revisions to its guidelines for oncologic products that would help accelerate the development and approval of anticancer agents.